PALO ALTO, Calif., Oct. 6, 2015 /PRNewswire/ — InCarda Therapeutics, Inc. (InCarda), a privately-held biotechnology company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, today announced the issuance of patents in the United States, Australia and Canada, which cover the company’s lead product candidate. The United States patent, No. 8,974,828, issued in March 2015 and is entitled “Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration.” InCarda’s lead product in development consists of an established drug for paroxysmal atrial fibrillation (PAF) delivered in a novel way, via inhalation.
“The issuance of this important patent strengthens the IP position around our product candidates, protecting our novel and exciting product platform. We continue to add to our patent estate with additional proprietary concepts we believe will transform cardiovascular care,” stated Grace E. Colón, Ph.D., chief executive officer and president of InCarda. “Delivery of effective cardiovascular medications through the pulmonary system may provide much quicker relief of symptoms and significantly reduce the burden on the healthcare system related to these cardiovascular episodes.”
“Flecainide is a first line drug of choice to treat Paroxysmal Atrial Fibrillation (PAF) in patients with minimal structural heart disease. At InCarda we are developing a fast acting inhaled version of this drug for quick relief from the disabling symptoms often experienced with an acute episode,” stated Narsi Rangachari, M. Pharm., chief operating officer, co-founder, and inventor on the patent. “Our products, given their pulmonary route of administration, have the unique potential to treat patients in the first moments following a cardiovascular event, and this could revolutionize the way these common events are treated,” added Carlos Schuler, Ph.D., chief scientific officer, co-founder and inventor on the patent.
InCarda’s Lead Product for PAF
Paroxysmal Atrial Fibrillation, the most common type of cardiac arrhythmia (abnormal heart rhythm) is an episode patients experience when the heart flutters instead of beating normally. Flecainide is commonly prescribed for arrhythmias, and InCarda is evaluating an inhaled formulation of the drug for patients experiencing PAF. Preparations are being made and a toxicology study is underway to optimize the product in advance of commencing a Phase 1 clinical trial in early 2016.
About InCarda (www.incardatherapeutics.com)
InCarda Therapeutics, located in the San Francisco Bay Area with operations in Australia, is focused on transforming cardiovascular disease treatment through pulmonary delivery of established drugs. The company is product-focused with significant capabilities and led by a team with extensive experience in drug development. The lead product under development is an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF). InCarda is also working on additional research concepts that leverage the same platform technology to target the heart for acute cardiac conditions. Our approach is designed to reduce the risk normally associated with drug development. Our model is based on the following three tenets: known diseases, known drugs, new delivery.
Cook Williams Communications, Inc.
SOURCE InCarda Therapeutics
Maverix Advances The State Of Gene Expression Analysis With Debut Of The Maverix RNA-Seq 3.0 Analysis Kit
SAN MATEO, Calif., Oct. 6, 2015 /PRNewswire/ — Maverix Biomics, Inc., a leading genomic analysis software company, today announced enhancements to its software portfolio with the debut of its RNA-Seq 3.0 gene expression analysis kit for differential expression in eukaryotes. The software is integrated into the Maverix Analytic Platform, which is a cloud-based genomic analysis solution that leverages proven open-source algorithms and applications to advance scientific discovery from next-generation sequencing efforts.
Dr. Garry Nolan’s laboratory at Stanford University has been using the Maverix RNASeq analysis kit to facilitate a deeper understanding of normal immune function, detailed substructures of cancer, auto-immunity, and pathogen effects upon the immune system. Postdoctoral fellow, Dr. Felice Alessio Bava, believes that the new kit has advanced his work in the study of epigenetic control of RNA signatures in cancer.
“As labs integrate various ‘omics disciplines, they must rapidly master new tools. The Maverix RNA-Seq software suite gave RNA experts in my lab—and even those new to the area—an accessible integrated “home” where workflows and analysis were managed through an intuitive interface. No more command line slash alphabet soup,” stated Dr. Nolan. “Welcome to the 21st Century for RNASeq analysis!”
Dr. Bava stated, “The Maverix RNA-Seq analysis kit saved us considerable time and effort, and provided us with accurate and insightful analyses that have aided our cancer studies. And, the Maverix platform is very easy for scientists to learn and use.”
Enhancements in the RNA-Seq 3.0 version include optimization for high throughput large-scale analysis projects, additional differential expression analysis tools, methods for the exploration of patterns in data, and support for more organisms, which now includes human, numerous animal models, plants, and fungi. And, the new “1-2-3-Launch” user experience, unique to Maverix analysis kits, makes it very simple for scientists, even without bioinformatics experience, to perform complex genomic analyses, and obtain meaningful results.
The Maverix mRNA-Seq analysis pipeline applies open-source tools, including a spliceaware aligner (either TopHat or STAR), in conjunction with differential expression analysis tools (Cufflinks, DESeq, and edgeR), to elucidate the transcriptome and analyze differential expression. Analysis results are provided through a variety of visual representations, including charts and tables, gene and sample correlation heatmaps, PCA scatter plots and histograms, and interactive heatmaps linked to a private version of the UCSC Genome Browser.
“Delivering the substantial improvements in our new RNA-Seq analysis kit demonstrates our commitment to the continuing development of our genomic and transcriptomic analysis solutions,” said Tom Kent, President of Maverix Biomics. “We are pleased that world renowned scientists are utilizing our technology to advance research that will ultimately have a positive impact on the understanding of devastating diseases, such as cancer.”
Maverix also provides analysis kits for Germline Variant Analysis, Somatic Variant Analysis, and Small RNA-Seq. And, Maverix supports a wide range of organisms, including human, animal models, Arabidopsis, and a variety of microorganisms.
About the Maverix Analytic Platform
The Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences researchers who may not have software or bioinformatics expertise. It leverages proven open-source algorithms and applications developed at leading academic and research centers. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analyses with reliable, scientifically vetted configurations, as cited in peer-reviewed journal publications. Visualizations are provided through a variety of integrated graphical tools, including a private, secure version of the UCSC Genome Browser, the world’s most widely used genome browser.
About Maverix Biomics
Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microorganisms. For more information, visit www.maverixbio.com.
SOURCE Maverix Biomics, Inc.
There was a meeting Monday in Washington, D.C., to discuss some of the latest advances in gene editing, a field that has profound medical, agricultural, social, and ethical implications for society….
[[Click headline to continue reading.]]
With sales in excess of $4.3 billion in 2014, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and…
From VWR International, LLC – 06 Oct 2015 07:49:06 GMT
– View all Sa…
AnaBios Corporation is a unique biotechnology Company. The Company employs its proprietary technology for testing the efficacy and safety of new drugs in human…
From Indeed – 06 Oct 2015 04:25:08 GMT
– View all San Diego jobs
We are looking for a Quality Control Technician for a great long-term opportunity. This position is responsible for performing a variety of microbiological testing and material inspection in a molecular biology laboratory, under the direct and consta […
We are looking to hire a Production Technician: Summary: Conducts bulk manufacturing of medical point-of-care diagnostic products. Responsible for production and manufacturing of lateral flow rapid test for enteric and infectious diseases. Works with […
San Diego-based Arena Pharmaceuticals (NASDAQ: ARNA) said that Jack Lief, who has served as Arena’s president and CEO since 1997, has retired from the company and left Arena’s board of…
[[Click headline to continue reading.]]
The California Institute for Biomedical Research (Calibr) is a not-for profit research institute located in La Jolla, California. Calibr is focused on innovative early stage translational research in collaboration with academic partners in the areas […
Start-up Biotech Company is seeking an enthusiastic and motivated person for a part-time Administrative/Marketing Assistant position at their office located in San Diego.
Candidate will assist with general clerical functions (order processing, order […